Visoluten
Also known as: Retina peptide bioregulator · Eye bioregulator
A retina/eye-derived peptide bioregulator studied in Russian research for ocular-tissue markers.
Visoluten at a glance
| Name | Visoluten |
|---|---|
| Also known as | Retina peptide bioregulator, Eye bioregulator |
| Category | Longevity |
| Type | Peptide |
| Sequence | Tissue-specific peptide fraction |
| Typical dose | Commonly cited around 1-3 mg per short course |
| Frequency | Short cyclical courses in the discussed protocols |
| Route | Subcutaneous or intramuscular injection (research); oral capsule forms also marketed |
| Half-life | Not well established. |
Overview
Visoluten is described in the bioregulator literature as a peptide preparation obtained from retinal and eye tissue. It is discussed in relation to age-related changes in ocular tissue and is often grouped with the pineal- and vision-adjacent bioregulators in longevity contexts. A short synthetic retina-associated peptide is referenced by some sources. The supporting data are largely from the originating Russian program, are older and non-Western, and remain outside mainstream ophthalmology's replicated evidence.
How it’s thought to work
- Proposed to act as a retina-specific peptide bioregulator influencing gene expression in ocular tissue.
- Discussed in relation to maintenance of retinal cell function with age.
- Claimed effects rest largely on in-house work and are not independently well established.
Researched uses
- Ocular-tissue and age-related vision research interest
- General longevity and tissue-maintenance discussions
- Cited alongside other organ-specific bioregulators
Commonly cited protocol
| Typical dose | Commonly cited around 1-3 mg per short course |
|---|---|
| Frequency | Short cyclical courses in the discussed protocols |
| Route | Subcutaneous or intramuscular injection (research); oral capsule forms also marketed |
| Notes | Typically described in cycles in the source literature. |
Reconstitution
Commonly a 5-10 mg vial; reconstitute with bacteriostatic water and use the calculator for units.
Visoluten dosage calculator
The calculator below is pre-filled with Visoluten’s commonly cited vial size and dose. Adjust the vial amount, bacteriostatic water, or dose to match your own vial — it will show the exact insulin-syringe units to draw, the concentration, and how many doses the vial holds.
Add 2 mL of bacteriostatic water to your 10 mg vial. That gives you about 5 doses of 2 mg. For each dose, draw 40 units into a 100-unit insulin syringe.
See the full Visoluten dosing chart (units for every dose & water amount), or open the full peptide calculator →
Cautions
- Not FDA-approved; a research compound, not an approved treatment for eye conditions.
- The evidence base is limited, older, and largely non-Western, and has not been widely replicated.
- Purity of research-grade or extract material varies by source.
- Vision changes should be assessed by a qualified eye-care professional rather than self-managed with peptides.
Visoluten FAQ
What is Visoluten?
A retina/eye-derived peptide bioregulator studied in Russian research for ocular-tissue markers.
How does Visoluten work?
Proposed to act as a retina-specific peptide bioregulator influencing gene expression in ocular tissue. Discussed in relation to maintenance of retinal cell function with age. Claimed effects rest largely on in-house work and are not independently well established.
What is Visoluten used for?
Ocular-tissue and age-related vision research interest; General longevity and tissue-maintenance discussions; Cited alongside other organ-specific bioregulators.
What is a typical Visoluten dose?
Commonly cited around 1-3 mg per short course, Short cyclical courses in the discussed protocols, Subcutaneous or intramuscular injection (research); oral capsule forms also marketed. This is a commonly cited figure for context only, not medical advice.
How do you reconstitute Visoluten?
Commonly a 5-10 mg vial; reconstitute with bacteriostatic water and use the calculator for units.
What is the half-life of Visoluten?
Not well established.